Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

The "In" Crowd

Related Content

FDA Accepts BLA for Amneal’s Denosumab Biosimilars

Biosimilars Webinar: Prosecution and Litigation Trends and Takeaways from BPCIA Litigation

Amgen and Fresenius Settle Denosumab BPCIA Case

Delaware's Corporate Advantages May Outweigh Benefits of Relocation

US Emerging as Top Global Medtech Destination

Federal Circuit Affirms Injunction Against Celltrion in Aflibercept BPCIA Litigation

Amgen Files Three IPR Petitions Challenging Bristol-Myers Squibb Anti-PD1 and Anti-CTLA-4 Antibody Combination Method of Treatment Patents

FDA Approves Celltrion’s Denosumab Biosimilars

Boston Forum: Merger Control & Competition in Life Sciences

Goodwin’s Annual Healthcare & Life Sciences Summit

Goodwin Advises Isomorphic Labs on Collaboration Expansion with Novartis

Gubra Enters $2.225 Billion License Agreement with AbbVie to Develop an Amylin Analog for the Treatment of Obesity

Goodwin Leads M&A, Private Equity, and Venture Capital League Table Rankings for 2024

Zealand and Roche Form Largest Single Asset Partnership Deal Worth up to $5.3 billion to Co-Develop and Co-Commercialize Petrelintide Monotherapy and Potential Combination Products in the U.S. and Europe as Therapy for Obesity

2seventy bio To Be Acquired by Bristol Myers Squibb for $5.00 per Share

BridgeBio Pharma Prices $575 Million Convertible Notes Offering

Life Sciences